How Fast Can You Lose Weight on Wegovy?

If you are considering Wegovy, it is completely natural to ask: “How quickly will I actually lose weight?”

This is one of the most-searched Wegovy questions — and also one of the most misunderstood. Wegovy is not designed to cause rapid weight loss, and the trial data shows clearly why a gradual curve produces better long-term results.

This guide covers the realistic timeline based on the pivotal STEP-1 clinical trial, what you can expect at each stage, how to set sensible kg targets based on your starting weight, what counts as a clinical “successful response”, and what happens when weight loss plateaus.

What “Fast” Actually Means With Wegovy

Weight loss on Wegovy is steady rather than rapid. Instead of dramatic drops in the first weeks, most patients experience gradual, cumulative changes that build over months. This is not a flaw — it is how the medication is designed to work, and it is reflected in every published clinical trial.

Early signs that Wegovy is starting to work usually appear before the scale moves significantly:

• Reduced appetite — hunger feels less constant
• Feeling full sooner — meals satisfy you with smaller portions
• Less snacking between meals — the urge to eat between meals fades
• Fewer cravings — particularly for high-calorie foods
• Quieter “food noise” — many patients describe feeling less mentally occupied by food

Visible weight loss usually follows these appetite changes by a few weeks. Patients who expect rapid drops in the first month often feel disappointed; patients who track appetite changes alongside the scale generally feel more reassured.

The STEP-1 Trial Timeline Week by Week

The STEP-1 clinical trial (Wilding et al., NEJM 2021) enrolled 1,961 adults with obesity or overweight with weight-related comorbidities. Participants received semaglutide 2.4mg or placebo over 68 weeks alongside lifestyle counselling. The trial produced the most detailed week-by-week weight loss data available for Wegovy.

Several patterns are worth noting:

• The first 16 weeks are the titration phase — weight loss is real but modest, with the body adjusting to each dose
• The steepest weight loss happens between weeks 16 and 40, once the maintenance dose is established
• The rate of loss slows after about week 40 as the body approaches its new equilibrium
• Loss continues at a slower rate to week 68 and typically plateaus shortly after

What This Looks Like in Kilograms

Percentage weight loss is the clinical standard, but most patients think in kilograms. The table below converts STEP-1’s average outcomes to realistic kg figures based on common UK starting weights.

These are average outcomes from a large trial — individual results vary substantially in both directions. Some patients in STEP-1 lost considerably more (32% lost ≥20% of body weight); others lost less than 5%. Your personal pace depends on multiple factors covered later in this guide.

The First Month: Setting the Foundation

Most patients begin Wegovy on the 0.25mg starter dose. This dose is designed to help the body adjust to GLP-1 effects — it is not designed to cause weight loss.

During the first four weeks, what is realistic:

• Average weight loss of around 2% by week 4 (about 2-3kg for most adults)
• Subtle appetite changes — food urgency softens, snacking decreases
• Some patients notice mild gastrointestinal effects (nausea, changes in bowel habits) — these are typically manageable
• The focus is comfort and tolerance, not the scale

If the first month feels slow, that is normal and expected. It does not mean treatment is not working — it means the medication is doing what the 0.25mg dose is designed to do. For the full dose progression: Wegovy dosages explained 0.25mg to 2.4mg.

Weeks 5-16: When Weight Loss Becomes Noticeable

As doses increase through 0.5mg, 1mg, and 1.7mg, weight loss becomes more visible and consistent.

The Maintenance Phase: Where Most Weight Loss Happens

From week 17 onwards, most patients are on the 2.4mg maintenance dose. This is where the steepest weight loss typically occurs in the STEP-1 trial — between weeks 16 and 40, average weight loss roughly doubles, from ~7% to ~12-13%.

What this looks like in practice:

• Reliable appetite control week to week
• Naturally smaller meals that satisfy
• Continued weight loss at roughly 1-2kg per month for most patients
• Greater confidence in the predictability of progress
• The cumulative effect becomes visible to others, not just on the scale

By week 52 (1 year of treatment), average weight loss in STEP-1 reached ~14%. This is when most patients see significant changes in body composition, clothing size, and health markers like blood pressure, lipids, and HbA1c.

What Counts as a Successful Response to Wegovy

Clinically, Wegovy is considered to be working when a patient achieves ≥5% weight loss by 12 weeks at the maintenance dose. This is the standard benchmark used by NICE and most prescribers.

Response rates from STEP-1 at week 68:

The majority of patients respond well to treatment. Around 14% of patients in STEP-1 lost less than 5% — these are sometimes called “non-responders” or “low-responders”. If your weight loss has stalled below 5% by 12 weeks at the maintenance dose, it’s worth a treatment review. Options include extending titration, reviewing dietary and lifestyle factors, or considering whether a different medication might suit you better.

The Plateau: When and Why It Happens

Weight loss on Wegovy typically continues for around 12-15 months before reaching a plateau. After this, the maintenance dose helps preserve the weight lost rather than driving further losses.

The plateau happens because:

• Your body has adapted to lower calorie intake
• Basal metabolic rate naturally decreases as body weight decreases
• The appetite-suppressing effect plateaus at the maintenance dose
• Your body reaches a new “set point” that it tries to defend

This is not a sign that treatment has stopped working — it is the expected long-term equilibrium. Most patients maintain their weight loss successfully on the maintenance dose, with small fluctuations either way.

If you want to continue losing weight after the plateau, options include:

• Reviewing eating patterns and macronutrient balance with clinical support
• Increasing activity levels gradually
• Discussing whether a different medication (such as Mounjaro) might produce additional loss
• Accepting the maintenance achieved as a successful outcome — 10-15% sustained weight loss has substantial long-term health benefits

Why Gradual Weight Loss Is Better

Slower, steady weight loss is often:

• Better at preserving muscle mass — rapid loss tends to come more from lean tissue
• Easier to maintain long-term — habits form alongside the medication’s effects
• Kinder to the body — reduced risk of gallstones, nutritional deficiencies, and metabolic disruption
• Less disruptive to energy and daily life — gradual reduction in intake is more tolerable
• More likely to result in lasting habit changes — slow change builds genuine new patterns

Patients who feel disappointed by the slow start often forget that the STEP-1 trial curve was deliberately gradual. The 15% average at 68 weeks is the result of a slow-and-steady approach, not despite it.

What Influences Your Personal Pace

Several factors affect how fast you lose weight on Wegovy, which is why individual outcomes vary significantly around the average curve:

• Starting weight and BMI — patients with higher starting weight typically lose more in absolute kg terms
• Maximum dose tolerated — patients who reach 2.4mg generally lose more than those who maintain at 1mg or 1.7mg
• Adherence to dosing — missed doses and gaps reduce cumulative exposure
• Eating patterns — Wegovy is licensed alongside a reduced-calorie diet; eating patterns that support the medication produce better results
• Protein intake — adequate protein helps preserve muscle and improves satiety
• Activity levels — even modest movement supports outcomes
• Sleep and stress — both affect appetite hormones beyond GLP-1
• Individual biology — genetic factors influence response to GLP-1 medications

This is why comparing your progress to others can be unhelpful — treatment outcomes are highly individual, and the variables are many.

For planning around treatment costs at different stages: Wegovy cost UK 2026: private prescription prices explained.

What Happens If You Stop Wegovy

One of the most important pieces of data on Wegovy comes from the STEP-4 trial (Rubino et al., JAMA 2021), which examined what happens when patients stop treatment after reaching the maintenance dose.

The findings were clear: patients who stopped Wegovy after 20 weeks of treatment regained approximately two-thirds of the weight they had lost over the following year, while patients who continued treatment maintained their loss.

This is consistent with how obesity is currently understood — as a chronic condition requiring ongoing treatment, similar to hypertension or type 2 diabetes. Stopping the medication that controls a chronic condition typically results in the condition returning.

Supporting Wegovy With Everyday Habits

Wegovy is licensed for use alongside a reduced-calorie diet and increased physical activity — not as a replacement for them. Trial results assume patients are also following lifestyle guidance. Habits that support the medication include:

• Regular meals, even if portions are smaller — skipping meals can intensify side effects and reduce protein intake
• Adequate protein (typically 1.2-1.6g per kg body weight) to preserve muscle during weight loss
• Staying well hydrated — at least 1.5-2 litres of fluids per day
• Gentle, consistent movement — even daily walks support outcomes and metabolic health
• Sleep quality — sleep deprivation increases appetite hormones beyond GLP-1’s reach
• Tracking progress beyond the scale — clothing fit, energy levels, sleep quality, joint comfort are all valid measures

It is not about doing everything perfectly — it is about consistency over many months.

Clinician-Led Support at Slinic

At Slinic, setting realistic expectations is a core part of safe, supportive care. Patients who understand the actual timeline tend to stay on treatment longer, manage early-stage uncertainty better, and achieve outcomes closer to the trial averages.

Shadeia Younis

Superintendent Pharmacist, Slinic (GPhC 2052119)

Patients at Slinic receive evidence-based guidance on what to realistically expect from Wegovy, when to be patient with the early titration phase, and when to consider whether their response merits a treatment review.

That clinical oversight is led by Shadeia Younis, our superintendent pharmacist, and is included in the monthly price rather than charged separately for follow-up reviews.

GPhC Registered Pharmacist GPhC No. 2052119 Superintendent Pharmacist, GPhC Pharmacy 1033729 Specialist in Weight Loss Treatment

Related Guides From Slinic

These guides go deeper on the topics most patients ask about alongside Wegovy timelines.

Frequently Asked Questions

Medical Disclaimer

This article provides educational information about typical Wegovy weight loss timelines based on clinical trial data and is not a substitute for professional medical advice. Wegovy (semaglutide) is a prescription-only medicine and should only be used together with a reduced-calorie diet and increased physical activity under appropriate clinical supervision. Always consult qualified healthcare providers before starting weight loss medication. Individual results vary substantially from trial averages — outcomes presented are population means with significant variation.